Detection of minimal residual disease (MRD) is increasingly used in the management of leukemia patients. A wide variety of methods have been developed and include technologies designed to detect residual malignant cells beyond the sensitivity of conventional approaches such as morphology and banding cytogenetics in leukemia. The choice of the best method depends on the biology of the individual malignancy, i.e. on the determination of specific markers which are useful to differentiate between leukemic cells and normal hematopoiesis in leukemic patients. These markers include leukocyte differentiation antigens, fusion transcripts, transcripts overexpressed by mutated or nonmutated genes, rearranged genes, and individual markers like polymorphic repetitive DNA sequences. The major technologies for MRD detection, their advantages and disadvantages and their clinical applications are discussed in this special issue - from `bench to bedside'. Providing a comprehensive overview on the significance of MRD in the evaluation, treatment and follow-up of hematologic malignancies, it will be of great value to hematologists, researchers interested in leukemias and lymphomas as well as laboratory technicians.
Publisher: S Karger AG
Number of pages: 120
Weight: 380 g
You may also be interested in...
Please sign in to write a review
Simply reserve online and pay at the counter when you collect. Available in shop from just two hours, subject to availability.
Thank you for your reservation
Your order is now being processed and we have sent a confirmation email to you at
When will my order be ready to collect?
Following the initial email, you will be contacted by the shop to confirm that your item is available for collection.
Call us on or send us an email at
Unfortunately there has been a problem with your order
Please try again or alternatively you can contact your chosen shop on or send us an email at